Elevated Triglycerides
Conditions
Brief summary
In this study, a lipase -sourced from a nonpyrogenic yeast, Candida rugosa, will be investigated to establish optimal TG levels in adults in a 12-week supplementation period. The investigational product provides a lipase formulation that is stable and active in acidic and neutral pH environments, while also fully digesting TGs into free fatty acids and glycerol which is beyond the scope of pancreatic lipase (Schuler et al. 2012). This will be a novel study investigating the effects of C. rugosa lipase on adults with slightly elevated TG levels.
Interventions
DIETARY_SUPPLEMENTGFA-918
Participants will be instructed to take one GFA-918 (125000 FIP Units of Lipase AY) capsule twice per day with their morning and evening meals for 12 weeks.
OTHERPlacebo
Participants will be instructed to take one Placebo capsule twice per day with their morning and evening meals for 12 weeks.
Sponsors
KGK Science Inc.
BIO-CAT Microbials, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Females and male within the age range of 30 to 70 at screening; 2. BMI of 20 - 34.9 kg/m2 at screening; 3. Not of child bearing potential, which is defined as females who have had hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with \> 1 year since last menstruation) OR, Female participants of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result, prior to enrollment. All hormonal birth controls require a minimum stability of three months and remain consistent throughout the study. Acceptable methods of birth control include: * Hormonal contraceptives; oral, hormone patch (Ortho Evra), vaginal ring (NuvaRing), injectable (Depo-Provera, Lunelle), or hormone implant (Norplant System) * Double-barrier method * Intrauterine devices * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) * Vasectomy of partner (shown successful as per appropriate follow-up); 4. Sedentary life style as defined by Sedentary Behavior Questionnaire (Appendix II) at screening; 5. Serum triglycerides 1.91 - 3.93 mmol/L (175 - 350 mg/dL) (inclusive) at screening; 6. Willing to maintain current levels of activity throughout the study; 7. Stable with no health concerns for participating in the study as determined by laboratory results, and medical history; 8. Willingness to complete all study visits and requirements associated with the study; 9. Has access to a computer, tablet, or smart phone with internet connection; 10. Has given voluntary, written, informed consent to participate in the study.
Exclusion criteria
1. Individuals who are pregnant, breastfeeding, or planning to become pregnant; 2. LDL-C ≥ 4.1 mmol/L (160 mg/dL); 3. Uncontrolled hypertension, defined as untreated systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 90 mmHg; 4. Cancer(s), except skin cancers completely excised with no chemotherapy or radiation with a negative follow up. and cancer(s) in full remission for more than five years after diagnosis 5. Immunocompromised individuals such as those that have undergone organ transplantation, those with rheumatoid arthritis, or those diagnosed with human immunodeficiency virus (HIV) or AIDS by verbal confirmation; 6. Verbal confirmation of current, or history of, bleeding disorders and/or medically prescribed anticoagulant/antiplatelet drugs (refer to Section 5.3); 7. Verbal confirmation of current unstable thyroid disease state; however, participants who have been on stable medication for \>6 months will be eligible to participate but will be assessed on a case by case basis by the QI. 8. Verbal confirmation of GI disorders and on anti-inflammatory drugs to control GI disorders; however, participants who have been on stable medication for \>6 months will be eligible to participate but will be assessed on a case by case basis by the QI 9. Verbal confirmation of Type I and Type II Diabetes; 10. Anti-inflammatory medication, corticosteroids, lipid lowering agents and diabetic medication (refer to Section 5.3) as assessed by the QI; 11. Alcohol or drug abuse within the last 6 months; 12. No more than 2 standard alcoholic drinks per day; 13. Verbal confirmation of marijuana use \>4 times a week 14. Tobacco products, including e-cigarette; dose and frequency will be assessed on a case by case basis by the QI 15. Participation in a clinical research study within 30 days of enrollment; 16. Allergy or sensitivity to study product ingredients; 17. Clinically significant abnormal laboratory results at screening; 18. Unstable medical conditions as assessed by the Qualified Investigator; 19. Individuals who are cognitively impaired and/or unable to give informed consent; 20. Any other condition which in the Qualified Investigator's opinion may adversely affect the participant's ability to complete the study or its measures or which may pose significant risk to the participant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change in levels of fasting serum TG levels | 12 weeks | The primary outcome of this study is the change in levels of fasting serum TG levels from screening to week 12 in fasting serum TG levels between GFA-918 and placebo groups. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The change in levels of total cholesterol | 12 weeks | The change from baseline to week 12 in lipid profile (levels of total cholesterol) between GFA-918 and placebo groups |
| The change in levels of LDL-cholesterol | 12 weeks | The change from baseline to week 12 in lipid profile ( levels of LDL-cholesterol) between GFA-918 and placebo groups |
| The change in levels of VLDL-cholesterol | 12 weeks | The change from baseline to week 12 in lipid profile (levels of VLDL-cholesterol) between GFA-918 and placebo groups |
| The change in levels of HDL-cholesterol | 12 weeks | The change from baseline to week 12 in lipid profile (levels of HDL-cholesterol) between GFA-918 and placebo groups |
| The change in levels of ApoA-I | 12 weeks | The change from baseline to week 12 in lipid profile (levels of ApoA-I) between GFA-918 and placebo groups |
| The change in levels of LDL-C: HDL-C | 12 weeks | The change from baseline to week 12 in lipid profile (LDL-C: HDL-C) between GFA-918 and placebo groups |
| The change in levels of TC: HDL-C | 12 weeks | The change from baseline to week 12 in lipid profile (TC: HDL-C) between GFA-918 and placebo groups |
| The change in levels of apolipoprotein A1 (ApoA-1) | 12 weeks | The change from baseline to week 12 in apolipoprotein A1 (levels of ApoA-1) between GFA-918 and placebo groups. |
| The change in levels of CRP | 12 weeks | The change from baseline to week 12 in levels of the inflammatory biomarker, CRP, between the GFA-918 and placebo groups |
| The change in levels of TNF-α | 12 weeks | The change from baseline to week 12 in levels of the inflammatory biomarker, TNF-α, between the GFA-918 and placebo groups |
| The change in levels of IL-6 | 12 weeks | The change from baseline to week 12 in levels of the inflammatory biomarker, IL-6, between the GFA-918 and placebo groups |
| The change in body weight | 12 weeks | The change from screening to week 12 in body weight between GFA-918 and placebo groups. |
| The change in levels of triglycerides | 12 weeks | The change from baseline to week 12 in lipid profile (levels of triglycerides) between GFA-918 and placebo groups |
| A clinically relevant change in TG after the 12-week supplementation with GFA-918 as assessed by a 1 mmol/L decrease in TG. | 12 weeks | 6A clinically relevant change in TG from screening to week 12 after the 12-week supplementation with GFA-918 as assessed by a 1 mmol/L decrease in TG. |
| A clinically relevant change in HDL-C after supplementation with GFA-918 defined as at least 0.026 mmol/L (1 mg/dL) or 1% increase | 12 weeks | A clinically relevant change in HDL-C, from baseline to week 12 after supplementation with GFA-918 defined as at least 0.026 mmol/L (1 mg/dL) or 1% increase |
| The clinically relevant change in LDL-C after supplementation with GFA-918 defined as a minimal 1% decrease | 12 weeks | The clinically relevant change in LDL-C, from baseline to week 12 after supplementation with GFA-918 defined as a minimal 1% decrease |
| The changes during the follow up period, week 12 to week 14, in levels of fasting serum TG levels | 14 weeks | The changes during the follow up period, week 12 to week 14, in fasting serum TG levels between GFA-918 and placebo groups. |
| The changes during the follow up period, week 12 to week 14, in complete lipid profile | 14 weeks | The changes during the follow up period, week 12 to week 14, complete lipid profile between GFA-918 and placebo groups. |
| The changes during the follow up period, week 12 to week 14, in levels of ApoA-1 | 14 weeks | The changes during the follow up period, week 12 to week 14, ApoA-1, between GFA-918 and placebo groups. |
| The changes during the follow up period, week 12 to week 14, in levels of inflammatory biomarkers | 14 weeks | The changes during the follow up period, week 12 to week 14, inflammatory biomarkers, between GFA-918 and placebo groups. |
| The changes during the follow up period, week 12 to week 14, in body weight | 14 weeks | The changes during the follow up period, week 12 to week 14, body weight between GFA-918 and placebo groups. |
| The changes during the follow up period, week 12 to week 14, in BMI | 14 weeks | The changes during the follow up period, week 12 to week 14, BMI, between GFA-918 and placebo groups. |
| The clinical significant changes during the follow up period, week 12 to week 14, in levels of TG | 14 weeks | The clinical significant changes during the follow up period, week 12 to week 14, in TG, between GFA-918 and placebo groups. |
| The clinical significant changes during the follow up period, week 12 to week 14, in levels of HDL-C | 14 weeks | The clinical significant changes during the follow up period, week 12 to week 14, in HDL-C, between GFA-918 and placebo groups. |
| The clinical significant changes during the follow up period, week 12 to week 14, in levels of LDL-C | 14 weeks | The clinical significant changes during the follow up period, week 12 to week 14, in LDL-C, between GFA-918 and placebo groups. |
| The change in body mass index (BMI) | 12 weeks | The change from screening to week 12 in body mass index (BMI) between the GFA-918 and placebo groups |
Other
| Measure | Time frame | Description |
|---|---|---|
| The incidence of adverse events with GFA-918. | 12 weeks | The incidence of adverse events during the 12-week supplementation with GFA-918. |
| The incidence of adverse events or abnormal safety outcomes during the follow up period, week 12 to week 14 | 14 weeks | The incidence of adverse events or abnormal safety outcomes during the follow up period, week 12 to week 14 |
| The incidence of any abnormal vital signs: blood pressure (BP) and heart rate (HR), with GFA-918 | 12 weeks | The incidence of any abnormal vital signs: blood pressure (BP) and heart rate (HR), during the 12-week supplementation with GFA-918 |
| The incidence of any abnormal ECG with GFA-918 | 12 weeks | The incidence of any abnormal ECG during the 12-week supplementation with GFA-918 |
| The incidence of any abnormal hematology (white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils) with GFA-918. | 12 weeks | The incidence of any abnormal hematology; white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils; during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal hematology; red blood cell (RBC) count, with GFA-918. | 12 weeks | The incidence of any abnormal hematology; hemoglobin, during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal hematology; hematocrit, with GFA-918. | 12 weeks | The incidence of any abnormal hematology; hematocrit, during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal hematology; platelet count, with GFA-918. | 12 weeks | The incidence of any abnormal hematology; platelet count, during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal hematology; RBC indices (mean corpuscular volume (MCV)) with GFA-918. | 12 weeks | The incidence of any abnormal hematology; RBC indices (mean corpuscular volume (MCV)), during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal hematology; RBC indices (mean corpuscular hemoglobin (MCH)), with GFA-918. | 12 weeks | The incidence of any abnormal hematology; RBC indices (mean corpuscular hemoglobin (MCH), during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal hematology; RBC indices (mean corpuscular hemoglobin concentration (MCHC)), with GFA-918. | 12 weeks | The incidence of any abnormal hematology; RBC indices (mean corpuscular hemoglobin concentration (MCHC)) during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal hematology; RBC indices (red cell distribution width (RDW)) with GFA-918. | 12 weeks | The incidence of any abnormal hematology; RBC indices (red cell distribution width (RDW)) during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal liver function measured: alanine aminotransferase (ALT), with GFA-918. | 12 weeks | The incidence of any abnormal liver function measured: alanine aminotransferase (ALT), during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal liver function measured: aspartate aminotransferase (AST), with GFA-918. | 12 weeks | The incidence of any abnormal liver function measured: aspartate aminotransferase (AST), during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal liver function measured: bilirubin, with GFA-918. | 12 weeks | The incidence of any abnormal liver function measured: bilirubin, during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal kidney function parameters: serum creatinine, with GFA-918 | 12 weeks | The incidence of any abnormal kidney function parameters: serum creatinine, during the 12-week supplementation with GFA-918 |
| The incidence of any abnormal kidney function parameters: estimated glomerular filtration rate (eGFR), with GFA-918 | 12 weeks | The incidence of any abnormal kidney function parameters: estimated glomerular filtration rate (eGFR), during the 12-week supplementation with GFA-918 |
| The incidence of any abnormal kidney function parameters: electrolytes (Na, K, Cl), with GFA-918 | 12 weeks | The incidence of any abnormal kidney function parameters: electrolytes (Na, K, Cl), during the 12-week supplementation with GFA-918 |
| The incidence of any abnormal urinalysis measurements: colour | 12 weeks | The incidence of any abnormal urinalysis measurements: colour, during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal urinalysis measurements: appearance | 12 weeks | The incidence of any abnormal urinalysis measurements: appearance, during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal urinalysis measurements: specific gravity | 12 weeks | The incidence of any abnormal urinalysis measurements: specific gravity, during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal urinalysis measurements: pH | 12 weeks | The incidence of any abnormal urinalysis measurements: pH, during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal urinalysis measurements: presence of protein | 12 weeks | The incidence of any abnormal urinalysis measurements: presence of protein, during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal urinalysis measurements: glucose | 12 weeks | The incidence of any abnormal urinalysis measurements: glucose, during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal urinalysis measurements: ketones | 12 weeks | The incidence of any abnormal urinalysis measurements: ketones, during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal urinalysis measurements: blood | 12 weeks | The incidence of any abnormal urinalysis measurements: blood, during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal urinalysis measurements: nitrites | 12 weeks | The incidence of any abnormal urinalysis measurements: nitrites, during the 12-week supplementation with GFA-918. |
| The incidence of any abnormal urinalysis measurements: leucocyte esterase | 12 weeks | The incidence of any abnormal urinalysis measurements: leucocyte esterase, during the 12-week supplementation with GFA-918. |
Countries
Canada
Outcome results
None listed